BioInvent plans ovarian cancer trial of BI-1808 triplet therapy in Q1 2027

• BioInvent will present updated Phase 1/2a results for BI-1808 with pembrolizumab in platinum-resistant recurrent ovarian cancer at ESMO on October 24, 2026.
• Earlier results presented at ASCO 2026 showed tumor responses and durable disease control, with few treatment-related discontinuations.
• The updated presentation will include a larger patient group; enrollment in the combination cohort is complete.
• A planned randomized trial will evaluate BI-1808, pembrolizumab and weekly paclitaxel, with or without bevacizumab.
• The trial is expected to start in the first quarter of 2027, with initial data expected in the second half, subject to enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 18, 2026, and is solely responsible for the information contained therein.